At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 651 enrolled
Drug / intervention
Herpes Zoster vaccine (GSK 1437173A)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Consistency, Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults 50 Years of Age or Older
In Brief
A Phase 3 clinical trial evaluating Herpes Zoster vaccine (GSK 1437173A) for Herpes Zoster and Herpes Zoster Vaccine. Completed, enrolled 651 participants across 8 sites in 3 countries.
Detailed Summary
The purpose of this study is to demonstrate lot-to-lot consistency in terms of immunogenicity, and evaluate safety of the Herpes Zoster subunit (HZ/su) vaccine. The study is designed as a randomized, double-blind study with three parallel groups.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHerpes Zoster, Herpes Zoster Vaccine
CountriesBelgium, Canada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 2014
Enrollment StartAug 2014
Primary CompletionApr 2015
Study CompletionApr 2016
TodayJul 2026
First PostedMar 3, 2014
Enrollment StartAug 13, 2014
Primary CompletionApr 29, 2015
Study CompletionApr 25, 2016
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 12.3 years ago
Interventions
Herpes Zoster vaccine (GSK 1437173A)biological
2 doses administered intramuscularly in deltoid region of non-dominant arm.